Moreover, several studies have evaluated the role of EZH2 overexpression in NSCLC and demonstrated that high EZH2 expression is correlated with the early pathogenesis, tumor progression, poor prognosis and poor overall survival for patients with NSCLC [11–14]. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.